Cargando…
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments
SIMPLE SUMMARY: HER2 positive breast cancer has been increasingly researched and its management improved. In all settings, it has been possible to improve both survival and quality of life with less aggressive and more effective treatments. The appearance of new drugs has made it possible to control...
Autores principales: | Morales, Serafin, Gasol, Ariadna, Sanchez, Douglas Rene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616515/ https://www.ncbi.nlm.nih.gov/pubmed/34830927 http://dx.doi.org/10.3390/cancers13225771 |
Ejemplares similares
-
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
por: Ferraro, Emanuela, et al.
Publicado: (2021) -
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer
por: Morales Murillo, Serafin, et al.
Publicado: (2021) -
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019) -
Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021) -
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
por: Bobrowicz, Malgorzata, et al.
Publicado: (2019)